Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

NCT00724984 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Hodgkin Disease
Lymphoma, Non-Hodgkin

Interventions

DRUG: PCI-24781

Sponsor

Pharmacyclics LLC.